UBS Asset Management Americas Inc. grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 109,141 shares of the medical research company’s stock after buying an additional 20,133 shares during the period. UBS Asset Management Americas Inc. owned approximately 0.23% of Charles River Laboratories International worth $11,040,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of CRL. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after acquiring an additional 202 shares during the period. Riverhead Capital Management LLC grew its position in Charles River Laboratories International by 14.7% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after buying an additional 247 shares during the period. Cambridge Advisors Inc. bought a new stake in Charles River Laboratories International during the second quarter valued at approximately $202,000. Advisor Partners LLC bought a new stake in Charles River Laboratories International during the second quarter valued at approximately $208,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Charles River Laboratories International during the second quarter valued at approximately $217,000. 95.38% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “UBS Asset Management Americas Inc. Raises Holdings in Charles River Laboratories International, Inc. (CRL)” was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at http://www.mareainformativa.com/ubs-asset-management-americas-inc-raises-holdings-in-charles-river-laboratories-international-inc-crl/117032/.

In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of Charles River Laboratories International stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director George Massaro sold 3,830 shares of Charles River Laboratories International stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $100.81, for a total value of $386,102.30. Following the completion of the transaction, the director now directly owns 18,731 shares of the company’s stock, valued at $1,888,272.11. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,529 shares of company stock worth $2,278,496. Insiders own 2.20% of the company’s stock.

Charles River Laboratories International, Inc. (NYSE CRL) traded up 0.29% on Friday, reaching $112.92. 250,821 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $108.08 and a 200 day moving average price of $98.13. The firm has a market cap of $5.37 billion, a PE ratio of 29.75 and a beta of 0.96. Charles River Laboratories International, Inc. has a one year low of $67.20 and a one year high of $113.83.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same quarter in the previous year, the firm earned $1.20 EPS. The company’s quarterly revenue was up 8.1% compared to the same quarter last year. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

A number of equities analysts have weighed in on CRL shares. Jefferies Group LLC upped their price target on shares of Charles River Laboratories International from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Robert W. Baird reiterated a “buy” rating and issued a $114.00 price target on shares of Charles River Laboratories International in a research report on Friday, September 1st. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 price target for the company. BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Finally, Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $100.50.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.